Biohaven Ltd (BHVN) News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments

Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments PR Newswire NEW HAVEN...

Form 8-K - Current report

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares PR Newswire NEW HAVEN, Conn., Oct...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Biohaven Announces Proposed Public Offering of Common Shares

Biohaven Announces Proposed Public Offering of Common Shares PR Newswire NEW HAVEN, Conn., Sept. 30, 2024 NEW...

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine

Biohaven Initiates Pivotal Trial of Novel Investigational Drug for Treatment of Migraine PR Newswire NEW...

Form 8-K - Current report

Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)

Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA) PR...

Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia PR...

Form 8-K - Current report

Form 424B7 - Prospectus [Rule 424(b)(7)]

Form 8-K - Current report